International Clinical Trial: Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07455006) titled 'Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients' on March 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Qilu Pharmaceutical Co., Ltd.

Condition: Thrombocytopenia, Immune

Intervention: Drug: QL0911

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: April 20, 2026

Target Sample Size: 60

To know more, visit https://clinicaltrials.gov/study/NCT07...